[α-[P-(二甲基氨基)苯基]-α-[4-(二甲基亚氨基)-2,5-环己二烯-1-亚基]-P-甲苯基]乙基二甲基铵氯溴化物 | 14855-76-6

• 物质功能分类: 分析化学 - 分析试剂 - 常用分析试剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: [α-[P-(二甲基氨基)苯基]-α-[4-(二甲基亚氨基)-2,5-环己二烯-1-亚基]-P-甲苯基]乙基二甲基铵氯溴化物
• 中文别名: 甲基绿；甲基綠；-[P-(二甲基氨基)苯基]-&alpha；-[4-(二甲基亚氨基)-2,5-环己二烯-1-亚基]-P-甲苯基]乙基二
• 英文名称: methyl Green
• 英文别名: [4-[[4-(dimethylamino)phenyl]-(4-dimethylazaniumylidenecyclohexa-2,5-dien-1-ylidene)methyl]phenyl]-ethyl-dimethylazanium;bromide;chloride
• CAS: 14855-76-6
• 化学式: Br*C₂₇H₃₅N₃*Cl
• 分子量: 516.952
• InChiKey: IDAQSADEMXDTKN-UHFFFAOYSA-L

物化性质

• 熔点：
  >300°C
• 溶解度：
  溶于水、乙醇；不溶于二甲苯
• 最大波长(λmax)：
  635nm, 420nm
• 稳定性/保质期：

  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  -1.01
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  6.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• TSCA：
  Yes

文献信息

• SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY
  申请人：Northwestern University

  公开号：US20170001976A1

  公开（公告）日：2017-01-05

  Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.

  公开了具有取代喹唑啉核心结构的新小分子，以及它们用于调节葡萄糖苷脂酶活性的用途。还公开了包含这些小分子或与小分子结合的激活葡萄糖苷脂酶的药物组合物，这些组合物可以用于治疗与葡萄糖苷脂酶活性相关的疾病或失调，包括神经系统疾病和失调，如戈谢病和帕金森病。
• Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
  申请人：Li Yunxiao

  公开号：US20090099253A1

  公开（公告）日：2009-04-16

  Internally masked neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.

  内部掩盖的新戊基磺酰酯前药，包含这种前药的药物组合物，以及使用这种前药和组合物治疗疾病的方法被披露。具体来说，披露了展现增强口服生物利用度的阿卡姆普罗酸前药以及使用阿卡姆普罗酸前药治疗神经退行性疾病、精神障碍、情绪障碍、焦虑障碍、躯体形式障碍、运动障碍、物质滥用障碍、暴饮暴食障碍、皮层扩散性抑郁相关障碍、耳鸣、睡眠障碍、多发性硬化症和疼痛的方法。
• [EN] SHIP INHIBITION TO COMBAT OBESITY<br/>[FR] INHIBITION DE SHIP DANS LE CADRE DE LA LUTTE CONTRE L'OBÉSITÉ
  申请人：UNIV NEW YORK STATE RES FOUND

  公开号：WO2015003003A1

  公开（公告）日：2015-01-08

  The present invention relates to the use of SHIP1 inhibitors and pan-SHIP1/2 inhibitors in various methods, including, without limitation: (i) a method to treat obesity or reduce body fat of an obese subject; (ii) a method to limit bone development in a subject suffering from an osteopetrotic or sclerotic disease; (iii) a method to treat or prevent diabetes; (iv) a method to reduce glucose intolerance or insulin resistance; and (v) a method to lower cholesterol.

  本发明涉及在各种方法中使用SHIP1抑制剂和全SHIP1/2抑制剂，包括但不限于：(i) 一种治疗肥胖或减少肥胖患者体脂的方法；(ii) 一种限制骨发育的方法，适用于患有骨质增生病或硬化疾病的患者；(iii) 一种治疗或预防糖尿病的方法；(iv) 一种减少葡萄糖耐量或胰岛素抵抗的方法；以及(v) 一种降低胆固醇的方法。
• [EN] FUMARATE ANALOGS AND USES THEREOF IN THE TREATMENT OF AN AUTOIMMUNE DISEASE OR AN INFLAMMATORY DISEASE<br/>[FR] ANALOGUES DE FUMARATE ET LEURS UTILISATIONS DANS LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE OU D'UNE MALADIE INFLAMMATOIRE
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2016022434A1

  公开（公告）日：2016-02-11

  Aspects of the present disclosure include compounds of formula (A) that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. Formula (A).

  本公开涉及的方案包括式（A）的化合物，该化合物可用于治疗各种自身免疫性和炎症性疾病和疾病。本公开的实施例还涉及包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。方案（A）。
• Reagents and methods for direct labeling of nucleotides
  申请人：Naleway John J.

  公开号：US20130150254A1

  公开（公告）日：2013-06-13

  The present invention provides systems and methods for production of activatable diazo-derivatives for use in labeling nucleotides. Labeling nucleotides is accomplished by contacting a stable hydrazide derivative of a detectable moiety with an activating polymer reagent which is used to directly label the nucleotide sample. Labeling occurs on the phosphate backbone of the nucleotide which does not perturb hybridization of the labeled nucleotide with its anti-sense strand. Since the method involves direct labeling, all types of nucleotides can be labeled without prior amplification or alteration.

  本发明提供了用于生产可激活重氮衍生物以用于标记核苷酸的系统和方法。通过将可检测基团的稳定的肼酰肼衍生物与用于直接标记核苷酸样品的活化聚合物试剂接触来完成核苷酸的标记。标记发生在核苷酸的磷酸骨架上，不会干扰标记核苷酸与其反义链的杂交。由于该方法涉及直接标记，所有类型的核苷酸都可以在不经过扩增或改变的情况下进行标记。